Telemetric Arrhythmia Diagnosis in Adults (TELEMARC1)
Primary Purpose
Atrial Fibrillation, Arrhythmia
Status
Unknown status
Phase
Not Applicable
Locations
Poland
Study Type
Interventional
Intervention
Prolonged telemetric Full Disclosure ECG recording.
Sponsored by
About this trial
This is an interventional diagnostic trial for Atrial Fibrillation focused on measuring Atrial fibrillation, Cardiac arrhythmia, ECG, Telemonitoring, Telemetry, Holter
Eligibility Criteria
Inclusion Criteria:
- Age - between 18 and 80 years old
- History of symptoms potentially caused by arrhythmia
- Symptoms occuring at least monthly
- Patient informed consent
- Declarative and feasible compliance (patient understands basic instructions regarding device use)
Exclusion Criteria:
- Evidence of previously recorded arrhythmia
- Inability to comply with the study protocol
- Lack of patient cooperation
Sites / Locations
- The Medical University of GdańskRecruiting
- Institute of CardiologyRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Telemetric ECG monitoring
Standard 24-hours Holter ECG recording
Arm Description
Telemetric 14-days Full Disclosure ECG recording.
Standard 24-hours Holter ECG recording repeated 3 times unless arrhythmia is diagnosed earlier.
Outcomes
Primary Outcome Measures
Recording of symptomatic or life threatening arrhythmia event
ECG monitoring is conducted until occurrence of symptomatic arrhythmia or life threatening arrhythmia but not longer than 14 days. Patients in the control group will have standard ECG Holter monitoring repeated 3 times unless arrhythmia is diagnosed earlier.
Secondary Outcome Measures
Quality of Life questionnaire and European Heart Rhythm Association (EHRA) scale assessment against evidence of cardiac arrhythmia occurrence.
Verification of patient self assessment based on the Quality of Life questionnaire and European Heart Rhythm Association (EHRA) scale against evidence of cardiac arrhythmia occurrence.
Silent (asymptomatic) arrhythmia events incidence detection assessment
Evaluation of silent (asymptomatic) arrhythmia events incidence which potentially could cause serious complications
Atrial fibrillation
Atrial flutter
Atrial Tachycardia
Ventricular tachycardia
Evaluation of stroke and bleeding risk factors incidence
Evaluation of stroke and bleeding risk factors incidence based on scores proposed in the European Society of Cardiology (ESC) guidelines: CHADS2VASC2 and HAS-BLED.
Full Information
NCT ID
NCT01265758
First Posted
December 21, 2010
Last Updated
February 18, 2013
Sponsor
National Institute of Cardiology, Warsaw, Poland
1. Study Identification
Unique Protocol Identification Number
NCT01265758
Brief Title
Telemetric Arrhythmia Diagnosis in Adults
Acronym
TELEMARC1
Official Title
OPTIMIZING DIAGNOSTICS AND THERAPY OF ARRHYTHMIA AND SYNCOPE EVENTS USING INTELLIGENT TELEMETRIC SOLUTIONS - Evaluation of Arrhythmia Diagnostics in Adults
Study Type
Interventional
2. Study Status
Record Verification Date
February 2013
Overall Recruitment Status
Unknown status
Study Start Date
February 2011 (undefined)
Primary Completion Date
March 2014 (Anticipated)
Study Completion Date
March 2014 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
National Institute of Cardiology, Warsaw, Poland
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to assess efficacy of prolonged Full Disclosure electrocardiogram (ECG) monitoring and signal analysis using advanced telemetric technology in comparison with a standard Holter ECG recording and an Event Holter recording to diagnose cardiac arrhythmia.
Detailed Description
Irregular and/or rapid beating of the heart called heart palpitations can occur in individuals without heart disease and the reasons for their palpitations are unknown. Together with heart palpitations silent arrhythmia may be present that could lead to serious complications (eg. stroke). In others, palpitations result from heart rhythm disturbances, sometimes life threatening. Standard diagnostic methods such as 24 hours Holter ECG monitoring or Event Holter do not guarantee early diagnosis of the arrhythmia. Prolonged heart rhythm recording and analysis using an automatic full disclosure telemetric device increase probability of arrhythmia diagnosis and early administration of applicable treatment. Study patients will be diagnosed using standard Holter ECG monitoring and 14 days telemetric full disclosure ECG monitoring. The full disclosure signal will be subsequently analyzed in the Event Monitoring mode by an independent consultant. Efficacy of Telemetric Monitoring in diagnosis of cardiac arrhythmia will be assessed in comparison with the standard Holter monitoring and Event Monitoring.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation, Arrhythmia
Keywords
Atrial fibrillation, Cardiac arrhythmia, ECG, Telemonitoring, Telemetry, Holter
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
360 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Telemetric ECG monitoring
Arm Type
Experimental
Arm Description
Telemetric 14-days Full Disclosure ECG recording.
Arm Title
Standard 24-hours Holter ECG recording
Arm Type
Active Comparator
Arm Description
Standard 24-hours Holter ECG recording repeated 3 times unless arrhythmia is diagnosed earlier.
Intervention Type
Device
Intervention Name(s)
Prolonged telemetric Full Disclosure ECG recording.
Other Intervention Name(s)
Medicalgorithmics, PocketECG
Intervention Description
Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
Primary Outcome Measure Information:
Title
Recording of symptomatic or life threatening arrhythmia event
Description
ECG monitoring is conducted until occurrence of symptomatic arrhythmia or life threatening arrhythmia but not longer than 14 days. Patients in the control group will have standard ECG Holter monitoring repeated 3 times unless arrhythmia is diagnosed earlier.
Time Frame
14 days
Secondary Outcome Measure Information:
Title
Quality of Life questionnaire and European Heart Rhythm Association (EHRA) scale assessment against evidence of cardiac arrhythmia occurrence.
Description
Verification of patient self assessment based on the Quality of Life questionnaire and European Heart Rhythm Association (EHRA) scale against evidence of cardiac arrhythmia occurrence.
Time Frame
14 days
Title
Silent (asymptomatic) arrhythmia events incidence detection assessment
Description
Evaluation of silent (asymptomatic) arrhythmia events incidence which potentially could cause serious complications
Atrial fibrillation
Atrial flutter
Atrial Tachycardia
Ventricular tachycardia
Time Frame
14 days
Title
Evaluation of stroke and bleeding risk factors incidence
Description
Evaluation of stroke and bleeding risk factors incidence based on scores proposed in the European Society of Cardiology (ESC) guidelines: CHADS2VASC2 and HAS-BLED.
Time Frame
14 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age - between 18 and 80 years old
History of symptoms potentially caused by arrhythmia
Symptoms occuring at least monthly
Patient informed consent
Declarative and feasible compliance (patient understands basic instructions regarding device use)
Exclusion Criteria:
Evidence of previously recorded arrhythmia
Inability to comply with the study protocol
Lack of patient cooperation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lukasz Szumowski, MD, PhD
Phone
+48501152728
Email
lszumowski@ikard.pl
First Name & Middle Initial & Last Name or Official Title & Degree
Zbigniew Jedynak, MD, PhD
Phone
+48603786780
Email
zjedynak@ikard.pl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lukasz J Szumowski, MD, PhD
Organizational Affiliation
National Institute of Cardiology, Warsaw, Poland
Official's Role
Study Chair
Facility Information:
Facility Name
The Medical University of Gdańsk
City
Gdansk
ZIP/Postal Code
80-210
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Janusz Siebert, Prof. MD PhD
Email
jsiebert@amg.gda.pl
First Name & Middle Initial & Last Name & Degree
Janusz Siebert, Prof. MD PhD
Facility Name
Institute of Cardiology
City
Warsaw
ZIP/Postal Code
04-628
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lukasz Szumowski, Prof,
Phone
+48 22 501152728
Email
lszumowski@ikard.pl
First Name & Middle Initial & Last Name & Degree
Lukasz Szumowski, Prof. MD PhD
12. IPD Sharing Statement
Learn more about this trial
Telemetric Arrhythmia Diagnosis in Adults
We'll reach out to this number within 24 hrs